Literature DB >> 9532168

Fas ligand expression on islets as well as multiple cell lines results in accelerated neutrophilic rejection.

S M Kang1, Z Lin, N L Ascher, P G Stock.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9532168     DOI： 10.1016/s0041-1345(97)01396-1

Source DB:  PubMed          Journal:  Transplant Proc        ISSN： 0041-1345            Impact factor:   1.066


× No keyword cloud information.
  7 in total

1.  Not so Fas: Re-evaluating the mechanisms of immune privilege and tumor escape.

Authors:  N P Restifo
Journal:  Nat Med       Date:  2000-05       Impact factor: 53.440

2.  Human melanoma cells do not express Fas (Apo-1/CD95) ligand.

Authors:  D B Chappell; T Z Zaks; S A Rosenberg; N P Restifo
Journal:  Cancer Res       Date:  1999-01-01       Impact factor: 12.701

Review 3.  Natural selection of tumor variants in the generation of "tumor escape" phenotypes.

Authors:  Hung T Khong; Nicholas P Restifo
Journal:  Nat Immunol       Date:  2002-11       Impact factor: 25.606

4.  Accelerating the induction of Fas-mediated T cell apoptosis: a strategy for transplant tolerance?

Authors:  H P Carroll; S Ali; J A Kirby
Journal:  Clin Exp Immunol       Date:  2001-12       Impact factor: 4.330

5.  Fas ligand exerts its pro-inflammatory effects via neutrophil recruitment but not activation.

Authors:  Peter J Dupont; Anthony N Warrens
Journal:  Immunology       Date:  2007-01       Impact factor: 7.397

6.  Fas/CD95 deficiency in ApcMin/+ mice increases intestinal tumor burden.

Authors:  Hector Guillen-Ahlers; Mark A Suckow; Francis J Castellino; Victoria A Ploplis
Journal:  PLoS One       Date:  2010-02-05       Impact factor: 3.240

Review 7.  Tumor evasion from T cell surveillance.

Authors:  Katrin Töpfer; Stefanie Kempe; Nadja Müller; Marc Schmitz; Michael Bachmann; Marc Cartellieri; Gabriele Schackert; Achim Temme
Journal:  J Biomed Biotechnol       Date:  2011-11-15
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.